Skip to content
Screener

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$8.69M-422%
Altimmune logo
AltimmuneALT
-$22.56M-15.3%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$158.33M-247%
Wave Life Sciences logo
Wave Life SciencesWVE
-$69.36M-37.4%
Arrowhead Research logo
Arrowhead ResearchARWR
-$132.73M-136%

Segments

By segment

See full
Reportable Segment-$57.94M-37.0%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050845
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(56,308)(47,202)(149,031)(126,513)
Interest income7,1048,22715,34717,597
Interest expense(7,940)(3,264)(15,759)(6,561)
Other expense, net(795)(42)(2,887)(42)
Net loss$(57,939)$(42,281)$(152,330)$(115,519)
Net loss per common, Series A preferred and Series B preferred share:
Basic and diluted net loss per common, Series A preferred, and Series B preferred share$(1.99)$(1.50)$(5.24)$(4.10)
Basic and diluted weighted average number of shares outstanding (Note 13)29,145,27128,232,60429,089,14828,159,333

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s net income?
Madrigal Pharmaceuticals, Inc. (MDGL) reported net income of -$57.94M in Q2 2026.
How has Madrigal Pharmaceuticals, Inc.'s net income changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s net income decreased by 37.0% year-over-year, from -$42.28M to -$57.94M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s net income?
Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s net income has grown at a 4.5% compound annual growth rate (CAGR), from -$241.85M to -$288.28M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude